





TAF7L Antibody

| | |
|----------------------------|--|
| Product Code | CSB-PA688972LA01HU |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
| Uniprot No. | Q5H9L4 |
| Immunogen | Recombinant Human Transcription initiation factor TFIID subunit 7-like protein (1-98AA) |
| Raised In | Rabbit |
| Species Reactivity | Human |
| Tested Applications | ELISA, IHC, IF; Recommended dilution: IHC:1:200-1:500, IF:1:50-1:200 |
| Form | Liquid |
| Conjugate | Non-conjugated |
| Storage Buffer | Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 |
| Purification Method | >95%, Protein G purified |
| Isotype | IgG |
| Clonality | Polyclonal |
| Alias | Transcription initiation factor TFIID subunit 7-like, Cancer/testis antigen 40, CT40, RNA polymerase II TBP-associated factor subunit Q, TATA box-binding protein-associated factor 50 kDa, Transcription initiation factor TFIID 50 kDa subunit, TAF7L, TAF2Q |
| Immunogen Species | Homo sapiens (Human) |
| Research Area | Epigenetics and Nuclear Signaling |
| Target Names | TAF7L |

Image



IHC image of CSB-PA688972LA01HU diluted at 1:300 and staining in paraffin-embedded human testis tissue performed on a Leica Bond™ system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.



Immunofluorescence staining of HepG2 cells with CSB-PA688972LA01HU at 1:100, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.